NU RISE start-up will test at Hospital da Luz Lisboa an innovating technological solution that allows to measure in real time and control the dose of radiotherapy administered to patients undergoing cancer treatments. The project was selected by Hospital da Luz Learning Health, Luz Saúde group company dedicated to advanced training, translational research and innovation in the providing and management of healthcare. The NU RISE solution emerged in the scope of the partnership between Hospital da Luz Learning Health and Maze – the European accelerator created by Fundação Calouste Gulbenkian, located in Lisbon and working exclusively with technological based start-ups whose solutions contribute to the 17 UN Sustainable Development Goals. Maze and its partners enable access to funds, competences and network, to start-ups presenting proposals to solve social and environmental challenges through their businesses. “NU RISE was selected to make this pilot study with us, for presenting a solution with great potential. It has the advantage of measuring radiotherapy dosage directly in the patient, with no need to alter the procedures applied by health professionals”, explains Gonçalo Luís, from the area of innovation of Hospital da Luz Learning Health. Already in the course of the process of selection of the start-up that would do the pilot study, the NU RISE solution was presented to the Hospital da Luz Lisboa Radiotherapy Service team, which confirmed its potential. “The tool presented by NU RISE stood out among the proposals of other start-ups, responding to a real need and presumably providing possibilities of implementation in a large company such as Luz Saúde”, adds Gonçalo Luís. After the tests performed on the equipment of Hospital da Luz Lisboa Radiotherapy Service, the solution will now be tested, in a first stage, in treatment simulations and a plan will be designed to test afterwards the solution in patients, that undergo radiotherapy treatments in this unit.
